BACKGROUND: Some studies have shown that human papillomavirus (HPV) infection may play not only an etiologic role in anogenital cancers but also a role in the clinical outcome. The objective of the current study was to determine whether detection of HPV DNA in primary squamous cell carcinomas of the upper aerodigestive tract (UADT) is a prognostic factor in patients with the disease. METHODS: The authors analyzed archival specimens of UADT tumors from 101 randomly selected patients with evaluable samples for HPV DNA detection. HPV testing was performed using a general primer-mediated polymerase chain reaction. RESULTS: The overall detection rate was 16.8% (17 of 101 specimens). HPV DNA was detected at higher rates in specimens from younger patients and in well-differentiated tumors. Pharyngeal tumors were more likely to be HPV positive (30.0%) than buccal (10.3%) or laryngeal tumors (15.4%), but the differences were not significant. The detection rate was similar for T1-T2 tumors (17.4%) and T3-T4 tumors (15.6%). However, tumors without lymph node metastasis were more likely to be HPV positive (21.4%) than tumors with lymph node involvement (6.5%). Kaplan-Meier and Cox regression survival analyses did not show any difference in overall or disease free survival according to HPV detection. CONCLUSIONS: Although the HPV DNA detection rate was slightly higher in local than in regionally spread tumors, our results support the hypothesis that it is very unlikely that HPV detection plays any role in the prognoses of patients with UADT squamous cell carcinoma.
BACKGROUND: Some studies have shown that human papillomavirus (HPV) infection may play not only an etiologic role in anogenital cancers but also a role in the clinical outcome. The objective of the current study was to determine whether detection of HPV DNA in primary squamous cell carcinomas of the upper aerodigestive tract (UADT) is a prognostic factor in patients with the disease. METHODS: The authors analyzed archival specimens of UADT tumors from 101 randomly selected patients with evaluable samples for HPV DNA detection. HPV testing was performed using a general primer-mediated polymerase chain reaction. RESULTS: The overall detection rate was 16.8% (17 of 101 specimens). HPV DNA was detected at higher rates in specimens from younger patients and in well-differentiated tumors. Pharyngeal tumors were more likely to be HPV positive (30.0%) than buccal (10.3%) or laryngeal tumors (15.4%), but the differences were not significant. The detection rate was similar for T1-T2 tumors (17.4%) and T3-T4 tumors (15.6%). However, tumors without lymph node metastasis were more likely to be HPV positive (21.4%) than tumors with lymph node involvement (6.5%). Kaplan-Meier and Cox regression survival analyses did not show any difference in overall or disease free survival according to HPV detection. CONCLUSIONS: Although the HPV DNA detection rate was slightly higher in local than in regionally spread tumors, our results support the hypothesis that it is very unlikely that HPV detection plays any role in the prognoses of patients with UADT squamous cell carcinoma.
Authors: G Szládek; A Juhász; G Kardos; K Szoke; T Major; I Sziklai; I Tar; I Márton; J Kónya; L Gergely; K Szarka Journal: J Clin Pathol Date: 2005-04 Impact factor: 3.411
Authors: J P Klussmann; S Dinh; O Guntinas-Lichius; C Wittekindt; S Weissenborn; U Wieland; H P Dienes; T Hoffmann; E Smith; L Turek; E J M Speel; H J Pfister Journal: HNO Date: 2004-03 Impact factor: 1.284
Authors: Francis P Worden; Bhavna Kumar; Julia S Lee; Gregory T Wolf; Kitrina G Cordell; Jeremy M G Taylor; Susan G Urba; Avraham Eisbruch; Theodoros N Teknos; Douglas B Chepeha; Mark E Prince; Christina I Tsien; Nisha J D'Silva; Kun Yang; David M Kurnit; Heidi L Mason; Tamara H Miller; Nancy E Wallace; Carol R Bradford; Thomas E Carey Journal: J Clin Oncol Date: 2008-05-12 Impact factor: 44.544
Authors: Paolo Boscolo-Rizzo; Maria Cristina Da Mosto; Roberto Fuson; Helena Frayle-Salamanca; Rossana Trevisan; Annarosa Del Mistro Journal: J Cancer Res Clin Oncol Date: 2008-10-08 Impact factor: 4.553